Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

KATHRYN R RIGONAN

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1336234210
CMS profile
196205
Location
FOUNTAIN VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$494.65

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $494.65 23

By paying entity

PY2023 · entire year · sorted by reported total

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

KATHRYN R RIGONAN

NPI 1336234210 · CMS profile ID 196205

Allopathic & Osteopathic Physicians / Internal Medicine

FOUNTAIN VALLEY, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1336234210?year=2023&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
KATHRYN R RIGONAN, NPI 1336234210, CMS profile ID 196205. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1336234210?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). KATHRYN R RIGONAN, NPI 1336234210, CMS profile ID 196205. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1336234210?year=2023&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
KATHRYN R RIGONAN, NPI 1336234210, CMS profile ID 196205, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1336234210?year=2023&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $494.65 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AstraZeneca Pharmaceuticals LP $24.3112/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015996933 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $31.1912/07/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 996920579 CMS
Amgen Inc. $25.1011/30/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019986493 CMS
AstraZeneca Pharmaceuticals LP $18.6311/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014214391 CMS
AstraZeneca Pharmaceuticals LP $0.7211/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015353305 CMS
AstraZeneca Pharmaceuticals LP $23.9111/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011671201 CMS
Lilly USA, LLC $34.6309/28/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031848277 CMS
AstraZeneca Pharmaceuticals LP $20.0209/14/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014829385 CMS
AstraZeneca Pharmaceuticals LP $22.3208/31/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011449451 CMS
AstraZeneca Pharmaceuticals LP $22.5808/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011623787 CMS
AstraZeneca Pharmaceuticals LP $19.0607/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011815485 CMS
AstraZeneca Pharmaceuticals LP $18.9506/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1014404217 CMS
AstraZeneca Pharmaceuticals LP $18.1905/24/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1015100313 CMS
Lilly USA, LLC $27.2405/11/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1031848273 CMS
AstraZeneca Pharmaceuticals LP $18.6604/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011543181 CMS
AstraZeneca Pharmaceuticals LP $26.7504/20/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011935587 CMS
Amgen Inc. $23.7704/13/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020614479 CMS
AstraZeneca Pharmaceuticals LP $22.3903/16/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1011346669 CMS
Amgen Inc. $30.3503/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1019986491 CMS
Merck Sharp & Dohme LLC $9.4903/02/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1048338057 CMS
AstraZeneca Pharmaceuticals LP $24.3002/09/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1012113307 CMS
AstraZeneca Pharmaceuticals LP $17.6502/01/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1016130639 CMS
Amgen Inc. $14.4401/05/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1020614477 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $828.15 37
PY2020 $182.39 11
PY2021 $25.18 4
PY2022 $392.24 18
PY2023 $494.65 23
PY2024 $418.99 21
PY2025 $477.76 21

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2024 Principal investigator $3,852.60 2
PY2023 Principal investigator $221,144.26 4
PY2022 Principal investigator $243,650.54 8
PY2021 Principal investigator $1,317.84 2
PY2020 Principal investigator $8,430.40 3
PY2019 Principal investigator $167,556.15 30

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme Corporation $1,110.00 12/17/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691497037
Principal investigator 1 Merck Sharp & Dohme Corporation $11,100.00 11/26/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691506825
Principal investigator 1 Merck Sharp & Dohme Corporation $550.00 11/19/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691507149
Principal investigator 1 Merck Sharp & Dohme Corporation $250.00 10/24/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691395167
Principal investigator 1 Merck Sharp & Dohme Corporation $25,375.20 10/24/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691395591
Principal investigator 1 Merck Sharp & Dohme Corporation $660.00 10/22/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691395105
Principal investigator 1 Merck Sharp & Dohme Corporation $3,440.00 10/01/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691395101
Principal investigator 1 Merck Sharp & Dohme Corporation $18,712.80 09/26/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691360108
Principal investigator 1 Merck Sharp & Dohme Corporation $372.00 09/21/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691510583
Principal investigator 1 Merck Sharp & Dohme Corporation $17.40 09/09/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691366266
Principal investigator 1 Merck Sharp & Dohme Corporation $193.17 09/07/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691442949
Principal investigator 1 Merck Sharp & Dohme Corporation $12,529.20 08/22/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691360099
Principal investigator 1 Merck Sharp & Dohme Corporation $300.00 08/22/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691360129
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 08/22/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691360203
Principal investigator 1 Merck Sharp & Dohme Corporation $9,516.00 08/08/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691359803
Principal investigator 1 Merck Sharp & Dohme Corporation $600.00 07/25/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691359370
Principal investigator 1 Merck Sharp & Dohme Corporation $558.00 07/01/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691497431
Principal investigator 1 Merck Sharp & Dohme Corporation $1,352.19 06/10/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691442431
Principal investigator 1 Merck Sharp & Dohme Corporation $1,041.60 06/09/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691482069
Principal investigator 1 Merck Sharp & Dohme Corporation $3,576.00 06/04/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691360144
Principal investigator 1 Merck Sharp & Dohme Corporation $810.79 05/14/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691359380
Principal investigator 1 Merck Sharp & Dohme Corporation $3,500.00 05/02/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691360139
Principal investigator 1 Merck Sharp & Dohme Corporation $500.00 05/02/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
Phase 3, Multicenter, Randomized, Double-blind, ActiveComparator-controlled, Lot-to-Lot Consistency Study to Evaluate the Safety, Tolerability,and Immunogenicity of V114 in Healthy Adults 50 Years of Age or Older PNEU-TRUE No dispute reported 06/30/2026 691360149
Principal investigator 1 Merck Sharp & Dohme Corporation $400.00 04/23/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691321797
Principal investigator 1 Merck Sharp & Dohme Corporation $7,632.00 02/26/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691325837
Principal investigator 1 Merck Sharp & Dohme Corporation $2,200.00 02/21/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691321789
Principal investigator 1 Merck Sharp & Dohme Corporation $13,356.00 01/24/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691311907
Principal investigator 1 Merck Sharp & Dohme Corporation $2,680.00 01/08/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691311685
Principal investigator 1 Merck Sharp & Dohme Corporation $1,900.00 01/08/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691311909
Principal investigator 1 Merck Sharp & Dohme Corporation $42,823.80 01/08/2019 Non-covered Recipient Entity
SOUTHLAND CLINICAL RESEARCH CENTER
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When administered Concomitantly with Influenza Vaccine in Healthy Adults 50 Years of Age or Older PNEU -FLU No dispute reported 06/30/2026 691311911